

## Supplementary material

### Supplementary Table 1

Real-time PCR primer sequences and gene accession identities.

### Supplementary Figure 1

Western showing Sox2 protein expression in glioma cell lines U-C12.6 MG, U-2987 MG, U-1242 MG, U-343 MG and U-87 MG. Sox2 expression is unchanged after stimulation with 250  $\mu$ M of cGMP analog in *Prkg2*-expressing U-2987-P6 glioma cells at indicated time points.

### Supplementary Figure 2

a) Western showing VASP (both phosphorylated and unphosphorylated bands), pAkt (Ser473) and pERK after 250  $\mu$ M cGMP analog treatment for 4 hours of U-2987 MG, U-2987-P3 and U-2987-P6 glioma cells (*Prkg2*-transfected). Antibodies for Akt and ERK phosphorylation were incubated together. b) Filter stripped from Figure 4 showing phosphorylated PDK1 protein levels in U-2987 MG and U-2987-P6 cells as well as total VASP protein expression and phosphorylation. The phosphorylated form of VASP protein could be detected as a slowly migrating band. c) Western showing pAkt and total Akt protein levels for a U-87 MG *Prkg2* clone (U-87-P1) treated with 250  $\mu$ M of cGMP analog at indicated time points.

### Supplementary Figure 3

Phenotypes of U-2987 MG, U-2987-P6, U-87 MG and U-87-P1 (*Prkg2*-transfected) cells treated 4h with 10 $\mu$ M LY294002 or a combination of 250  $\mu$ M cGMP analog and 0.5mM

IBMX. Photographed at 20x magnification (or 60x in small picture) when grown in cell culture media.

#### **Supplementary Figure 4**

a) Relative expression of *PDGFR $\alpha$*  of untreated glioma cell lines transfected with empty pcDNA vector as compared to corresponding *Prkg2* clones. *PDGFR $\alpha$*  expression in glioma cell clones transfected with empty pcDNA vector (denoted U-2987 MG, U-87 MG, U-343 MG and U-1242 MG) was set to 1 for each individual cell line (not to mistake with the absolute *PDGFR $\alpha$*  expression in the cell lines (not shown)). Expression was normalized to *GAPDH*. b) Chart of *SOX9* mRNA expression in U-2987 MG and U-2987-P6 cells after 4h of 250  $\mu$ M cGMP analog treatment. c) Immunostaining of GFAP, TuJ1 and Sox9 in U2987 MG and U2987-P6 cells grown in serum with or without 72 h of cGMP analog treatment. Sox9 levels were apparently lower in cGMP-treated U-2987-P6 cells but any significantly different distribution patterns were not found after counting positively stained cells.

#### **Supplementary Figure 5**

a) Representative pictures of neurospheres of U-2987 MG and U-2987-P6 cells after 72 hours, 1 week and 3 weeks of culturing in Neurobasal media supplemented with EGF and FGF. b) Real-time PCR of *SOX9* expression levels in glioma cell lines cultured in 10% serum or 1 week in Neurobasal media (supplemented with EGF and FGF) as compared to total adult brain RNA. d) Distribution of cells counted positive for GFAP/Sox9 (co-stained), TuJ1 (only), TuJ1/Sox9 (co-stained), GFAP/TuJ1 (co-stained) and GFAP (only). Very few Sox9-only positive cells were found even when increasing the confocal Zeiss LSM 510 laser to maximum powers.


## Supplementary Table 1

**Table 1. Real-time PCR primers**

Primer (gene)	Accession ID	Primer sequences (forward / reverse)
<i>CDI33</i>	NM_006017	TACCAAGGACAAGGCGTTCACAGA GTGCAAGCTCTTCAAGGTGCTGTT
<i>GAPDH</i>	NM_002046	ACATCAAGAAGGTGGTGAAGCAGG TGTCGCTGTTGAAGTCAGAGGAGA
<i>GFAP</i>	NM_002055	TCTGGAGAGGAAGATTGAGTCGCT CATACTGCGTGC GGATCTCTTTCA
<i>MAP2</i>	NM_002374	TAACCAACCACTGCCAGACCTGAA AGCCACATTTGGATGTCACATGGC
<i>NES</i>	NM_006617	ACTGGAGTCTGTGGAAGTGAACCA TTGGTACTCTCCCTTTCCCAGGTT
<i>PDGFRA</i>	NM_006206	TGGTTGAAGGAACAGCCTATGG TGGCCGTGGGTTTTAGCAT
<i>PLP</i>	NM_000533	CTTCCCCAGCAAGACCTCTG AAAGCATTCCATGGGAGAACA
<i>PRKG2</i>	NM_006259	AGTAACACAGAGCACAGAAGGCCA CATCACGGTTCAGGTTTGCCACAT
<i>SOX9</i>	NM_000346	TCAACGGCTCCAGCAAGAACAAG ACTTGTAATCCGGGTGGTCCTTCT
<i>TuJ1</i>	NM_006086	ACAACGAGGCCTCTTCTACAAGT TAGTGACCCTTGCCCCAGTTGTTG


\*Sequences were designed with Primer Express 1.5a software (Applied Biosystems) or by using the Integrated DNA Technology PrimerQuest (<http://eu.idtdna.com/Scitools/Applications/Primerquest/>). If possible, forward and reverse primers were designed aligning different exons. Absolute specificity was confirmed with National Center for Biotechnology Information (NCBI), BLAST and ENSEMBL genome browser (<http://www.ensembl.org>) searches.

Supplementary Figure 1




## Supplementary Figure 2


a)




b)




c)



Supplementary Figure 3




## Supplementary Figure 4




## Supplementary Figure 5

a)



b)



c)

